The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.
Junyao Xu
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose
Ming Sound Tsao
No relevant relationships to disclose
Eric Xueyu Chen
No relevant relationships to disclose
Pinjiang Cao
No relevant relationships to disclose
Chow Sue
No relevant relationships to disclose
Stefano Serra
No relevant relationships to disclose
David W Hedley
No relevant relationships to disclose